Session Information
Session Title: AA 2021 Virtual Posters - Pandemic
Session Time: None. Available on demand.
Disclosures: Amit Sharma, MD: No financial relationships or conflicts of interest
Case Diagnosis: 72 year old female presenting with Acute Inflammatory Demyelinating Polyneuropathy
Case Description: A 72 year old female with past medical history of breast cancer status post bilateral mastectomies and hormone replacement therapy (in remission) presented with worsening lower extremity weakness that began 48 hours after receiving the second dose of the Moderna COVID vaccine. Patient also endorsed numbness and tingling along with reduced sensation to hands, forearms, waist, and lower extremities. Imaging, including MRI spine, was negative for any acute process or radicular abnormalities. An LP was performed and revealed a high-normal protein level with all other CSF studies being negative. Patient received 5 days of IVIG at a rate of 0.4 mg/kg, with improvement in strength but still endorsed symptoms of diffuse weakness in the lower extremities as well as gait instability. Patient was then admitted to our Acute Inpatient Rehabilitation Program.
Setting: Inpatient Rehabilitation Facility.Assessment/
Results: Timely administration of IVIG delayed the progression of AIDP secondary to Moderna COVID vaccine dose #2 and intensive rehabilitation in an acute rehabilitation setting led to improvement in strength and function.
Discussion: After a thorough literature review, this is the first reported case, to our knowledge, of Acute Inflammatory Demyelinating Polyneuropathy (AIDP) secondary to Moderna COVID vaccination.
Conclusion: AIDP from the Moderna COVID vaccine is a possible outcome that clinicians should be aware of as prompt intervention can significantly improve outcomes. Further studies are warranted to determine the prevalence of this negative outcome in relation to the Moderna vaccine.
Level of Evidence: Level IV
To cite this abstract in AMA style:
Sharma A, Gosai E. Acute Inflammatory Demyelinating Polyneuropathy Secondary to Moderna COVID Vaccine Dose #2: A Case Report [abstract]. PM R. 2021; 13(S1)(suppl 1). https://pmrjabstracts.org/abstract/acute-inflammatory-demyelinating-polyneuropathy-secondary-to-moderna-covid-vaccine-dose-2-a-case-report/. Accessed May 11, 2025.« Back to AAPM&R Annual Assembly 2021
PM&R Meeting Abstracts - https://pmrjabstracts.org/abstract/acute-inflammatory-demyelinating-polyneuropathy-secondary-to-moderna-covid-vaccine-dose-2-a-case-report/